CoChat

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Open access
Heerspink, Hiddo J L, Jongs, Niels, Chertow, Glenn M, Langkilde, Anna Maria, McMurray, John J V, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C David, Stefansson, Bergur V, Toto, Robert D, Wheeler, David C, Greene, Tom · 2021 · The Lancet Diabetes & Endocrinology
Cited by 206

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)—ie, the eGFR slope. Methods DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatinine ratio (UACR) of 200–5000 mg/g, and an eGFR of 25–75 mL/min per 1·73m 2 . Participants were randomly assigned (1:1) to oral dapagliflozin 10 mg once daily or placebo, added to standard care. In this pre-specified analysis, we analysed eGFR slope using mixed-effect models with different slopes from baseline to week 2 (acute eGFR decline), week 2 to end of treatment (chronic eGFR slope), and baseline to end of treatment (total eGFR slope). DAPA-CKD is registered with ClinicalTrials.gov, NCT03036150, and is now complete. Findings Between Feb 2, 2017, and April 3, 2020, 4304 participants were recruited, of whom 2152 (50%) were assigned to dapagliflozin and 2152 (50%) were assigned to placebo. At baseline, the mean age was 62 years (SD 12), 1425 (33·1%) participants were women, 2906 (67·5%) participants had type 2 diabetes. The median on-treatment follow-up was 2·3 years (IQR 1·8–2·6). From baseline to the end of treatment, dapagliflozin compared with placebo slowed eGFR decline by 0·95 mL/min per 1·73 m 2 per year (95% CI 0·63 to 1·27) in the overall cohort. Between baseline and week 2, dapagliflozin compared with placebo resulted in an acute eGFR decline of 2·61 mL/min per 1·73 m 2 (2·16 to 3·06) in patients with type 2 diabetes and 2·01 mL/min per 1·73 m 2 (1·36 to 2·66) in those without type 2 diabetes. Between week 2 and end of treatment, dapagliflozin compared with placebo reduced the mean rate of eGFR decline by a greater amount in patients with type 2 diabetes (mean difference in chronic eGFR slope 2·26 mL/min per 1·73 m 2 per year [1·88 to 2·64]) than in those without type 2 diabetes (1·29 mL/min per 1·73 m 2 per year [0·73 to 1·85]; p interaction =0·0049). Between baseline and end of treatment, the effect of dapagliflozin compared with placebo on the decline of total eGFR slope in patients with type 2 diabetes was 1·18 mL/min per 1·73 m 2 per year (0·79 to 1·56) and without type 2 diabetes was 0·46 mL/min per 1·73 m 2 per year (–0·10 to 1·03; p interaction =0·040). The total eGFR slope was steeper in patients with higher baseline HbA 1c and UACR; the effect of dapagliflozin on eGFR slope was also more pronounced in patients with higher baseline HbA 1c and UACR. Interpretation Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA 1c , and higher UACR. Funding AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(21)00242-4

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 206

Metadata

Authors
Heerspink, H. J. L., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Stefansson, B. V., Toto, R. D., Wheeler, D. C., & Greene, T.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2021-11
Volume
9
Issue
11
Pages
743-754
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3201867211
Cited by
206
References
11
FWCI
18.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00242-4
The paper
Heerspink, H. J. L., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Stefansson, B. V., Toto, R. D., Wheeler, D. C., & Greene, T. (2021). Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00242-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.